Older Age Threshold for Oxaliplatin Benefit in Stage II to III Colorectal Cancer.

ABSTRACT:

Importance

Colorectal cancer is a leading cause of cancer mortality, with increasing incidence in older adults. Oxaliplatin-based adjuvant chemotherapy is standard for stage II to III colorectal cancer, but its benefit in older patients remains unclear.

Objective

To investigate whether there is an optimal age threshold for a survival benefit of adding oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy in older patients with stage II to III colorectal cancer.

Design, setting, and participants

This population-based, retrospective cohort study using data from the Korea Health Insurance Review and Assessment Service included patients who underwent curative resection for stage II to III colorectal cancer and received adjuvant chemotherapy between January 2014 and

SUBMITTER: Bong JW 

PROVIDER: S-EPMC12329608 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature